PG Course-LV
Nov. 15 (Thu)
09:00-10:30
Recent progress in the management of chronic liver diseases 103 (1F)
Chairperson(s) Diana Payawal (Manila), Jinmo Yang (Suwon)
09:00-09:20 Strategies for HBV cure beyond strong viral suppression Sang Hoon Ahn
(Seoul)
09:20-09:40 Update of concept and pharmacological therapies in nonalcoholic fatty liver disease Etsuko Hashimoto
(Tokyo)
09:40-10:00 Recent updates in the management of cirrhosis complication: SBP, ascites and varix bleeding Ashish Kumar
(New Delhi)
10:00-10:20 Differences in HCC treatment strategies: Eastern vs Western Perspectives Joong-Won Park
(Goyang)
10:20-10:30 Q&As
Symposium LV-K-01 (Korean)
Nov. 15 (Thu)
Changing paradigms in the management of chronic liver disease 105 (1F)
Chairperson(s) Joon-Yeol Han (Seoul), Han Chu Lee (Seoul)
11:00-11:20 Chronic hepatitis B in special situation(during pregnancy and immunospressive therapy) Sae Hwan Lee
(Cheonan)
11:20-11:40 Chronic hepatitis C in serious cases(renal insufficiency, decompensated cirrhosis and HCC) Hana Park
(Seongnam)
11:40-12:00 Severe alcoholic hepatitis in alcoholic liver disease Eileen L. Yoon
(Seoul)
12:00-12:20 Non-alcoholic steatohepatitis; Current and future treatment options Hwi Young Kim
(Seoul)
12:20-12:30 Q & A
Symposium LV-K-02 (Korean)
Nov. 15 (Thu)
General review of rare liver diseases 105 (1F)
Chairperson(s) Kwan Soo Byun (Seoul), Si-Hyun Bae (Seoul)
14:00-14:20 Wilson's disease Hyun Chin Cho
(Jinju)
14:20-14:40 Autoimmune hepatitis Yanghyun Baek
(Busan)
14:40-15:00 Primary biliary cholangitis Hee Yeon Kim
(Uljeongbu)
15:00-15:20 Portal vein thrombosis Nae-Yun Heo
(Busan)
15:20-15:30 Q & A
Free Paper (LV 1) (English)
Nov. 15 (Thu)
14:00-15:30
KDDW Free Paper (LV 01) E3+4 (3F)
Chairperson(s) Soonho Um (Seoul), Neung Hwa Park (Ulsan)
14:00-14:10 Oral branched chain amino acids in patients with hepatocellular carcinoma for transarterial chemoembolization: A meta-analysis Elvie Victonette Blanco Razon-Gonzalez
(Iloilo)
14:10-14:20 Histopathological heterogeneity in hepatocellular carcinoma: The molecular link Manoj Kumar Sahu
(Bhubaneswar)
14:20-14:30 A comparison of risk score models to predict the risk of HCC in chronic hepatitis B patients in Thailand Thanachote Kamalapirat
(Bangkok)
14:30-14:40 Epidemiological, management and barcelona clinic liver cancer staging status of hepatocellular carcinoma: Experience of a tertiary care center. Talha Qureshi
(Karachi)
14:40-14:50 Elasticity characterization of malignant and benign liver lesions by shear wave elastography Anoop K
(Trivandrum)
Chairperson(s) Soonho Um (Seoul), Hee Bok Chae (Cheongju)
14:50-15:00 Factors associated with virological relapse after stopping entecavir therapy in chronic hepatitis B patients Chien-Jui Huang
(Tainan)
15:00-15:10 Frequency and clinical response of Sofosbuvir, Daclatasvir and Ribavirin in patients of chronic Hepatitis C undergoing hemodialysis Ghulam Basit Mahesar
(Karachi)
15:10-15:20 Fibroscan in asymptomatic alcoholics Tejaswini Dande
(Chennai)
15:20-15:30 Development of a new scoring system (EVMAN scoring sytem) for assessment of Hepatic Encephalopathy (HE) Jose Mathew
(Thiruvananthapuram)
Symposium LV-K-03 (Korean)
Nov. 15 (Thu)
Management of cormobidity in liver disease 105 (1F)
Chairperson(s) Byung Ho Kim (Seoul), Joon Hyoek Lee (Seoul)
16:00-16:20 Geneal and liver specific management of hypertension Hae Young Lee
(Seoul)
16:20-16:40 Geneal and liver specific selection of antibotics and vaccine Yu Bin Seo
(Seoul)
16:40-17:00 Geneal and liver specific management of obesity Yong-Ho Lee
(Seoul)
17:00-17:20 Geneal and liver specific management of psychiatric disorder Jung-Seok Choi
(Seoul)
17:20-17:30 Q & A
Free Paper (LV 2) (Korean)
Nov. 15 (Thu)
16:00-17:30
KDDW Free Paper (LV 02) E3+4 (3F)
Chairperson(s) Chul Ju Han (Seoul), Jeong Ill Suh (Gyeongju)
16:00-16:10 Longitudinal assessment of three serum biomarkers to detect very early stage hepatocellular carcinoma Jonggi Choi
(Seoul)
16:10-16:20 Conventional TACE is superior approach to super-selective TACE for tumor necrosis of HCC - a single center experience Joonho Jeong
(Busan)
16:20-16:30 Postembolization syndrome after transcatheter arterial chemoembolization for hepatocellular carcinoma : Incidence and risk factor analysis Hyun Jin Baek
(Cheonan)
16:30-16:40 Preoperative blood neutrophil counts predicts survival in patients with hepatocellular carcinoma undergoing living donor liver transplantation Young Mi Hong
(Yangsan)
16:40-16:50 Hepatitis C virus genotype 3 was associated with the development of hepatocellular carcinoma in an Asian population Sang Soo Lee
(Changwon)
Chairperson(s) Won-Choong Choi (Seoul), Il Han Song (Cheonan)
16:50-17:00 The risk of hbv reactivation among HBV/HCV co-infected patients treated with direct-acting antiviral agents; a single center experience Young Joo Park
(Busan)
17:00-17:10 The need for chronic hepatitis C treatment in patients with breast cancer undergoing chemotherapy Kwang Il Seo
(Busan)
17:10-17:20 Clinical features and outcomes of epstein-barr viral hepatitis; Single center experience Yongho Jang
(Cheonan)
17:20-17:30 Effects of seasonal and temperature variations on variceal bleeding in Korean children Sowon Park
(Seoul)
Symposium LV-01
Nov. 16 (Fri)
08:30-10:00
Chronic hepatitis B: current medication 103 (1F)
Chairperson(s) Seung Kew Yoon (Seoul), George Lau (Hong Kong)
08:30-08:50 Can we stop the neucleot(s)ide analogue? George Lau
(Hong Kong)
08:50-09:10 Prevention of new HBV infection: nucleotide analogue in pregnant women and vaccination Henry LY Chan
(Hong Kong)
09:10-09:30 HBV and HCV coinfection Jidong Jia
(Beijing)
09:30-09:50 Bepatitis B prophylaxis and occult hepatitis B in immunocompromized patients: to whom and how long Seng Gee Lim
(Singapore)
09:50-10:00 Q&As
PG Course-LV (Korean)
Nov. 16 (Fri)
08:30-10:00
Concerning points and management during treatment for liver disease E1+2 (3F)
Chairperson(s) So Young Kwon (Seoul), June Sung Lee (Goyang)
08:30-08:50 During antiviral therapy for HBV Hyun Phil Shin
(Seoul)
08:50-09:10 During antiviral therapy for HCV In Hee Kim
(Jeonju)
09:10-09:30 During imunosuppressive therapy for Autoimmune liver disease Eun Ju Cho
(Seoul)
09:30-09:50 During systemic therapy for HCC Sung-Bum Cho
(Gwangju)
09:50-10:00 Q&As
Symposium LV-02
Nov. 16 (Fri)
14:00-15:30
Chronic hepatitis B: future treatment for the cure 103 (1F)
Chairperson(s) Seung Woon Paik (Seoul), Shiv Kumar Sarin (New Delhi)
14:00-14:20 Potential therapeutic target in hepatitis B virus life cycle Jia-Horng Kao
(Taipei)
14:20-14:40 Current strategies to maximize HBsAg loss in patients with CHB Pietro Lampertico
(Milan)
14:40-15:00 Immunologic modulation for hepatitis B treatment Antonio Bertoletti
(Singapore)
15:00-15:20 Emerging drugs?& new therapeutic perspectives?for HBV Henry LY Chan
(Hong Kong)
15:20-15:30 Q&As
Symposium LV-03
Nov. 16 (Fri)
16:00-17:30
Chronic hepatitis C in DAA era 103 (1F)
Chairperson(s) Kwan Soo Byun (Seoul), Rakesh Aggarwal (Lucknow)
16:00-16:20 HCV screening in general population: is this cost-effective in DAA era? Rakesh Aggarwal
(Lucknow)
16:20-16:40 Is there difficult to treat population in HCV patients in DAA era? Naoya Sakamoto
(Sapporo)
16:40-17:00 Increased risk of HCC following DAA: fact or fiction?/Follow up strategy after SVR in chronic hepatitis C Yasuhiro Asahina
(Tokyo)
17:00-17:20 DAA first versus transplantation first in decompensated cirrhotic HCV patients Young-Suk Lim
(Seoul)
17:20-17:30 Q&As
Symposium LV-04
Nov. 17 (Sat)
17:20-17:30
Current advances in non-alcoholic fatty liver disease 101 (1F)
Chairperson(s) Kwang-Hyub Han (Seoul), Jacob George (Westmead)
08:30-08:50 New trends on obesity and NAFLD in Asia Vincent Wong
(Hong Kong)
08:50-09:10 Interactions between bile acids and nuclear receptors in NAFLD Etsuko Hashimoto
(Tokyo)
09:10-09:30 Clinical trial design and optimal endpoints for nonalcoholic steatohepatitis Won Kim
(Seoul)
09:30-09:50 Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease Jacob George
(Westmead)
09:50-10:00 Q&As
Symposium LV-05
Nov. 17 (Sat)
10:30-12:00
Recent advances in the management of hepatocellular carcinoma 101 (1F)
Chairperson(s) Joong-Won Park (Goyang), Jose Decena Sollano (Manila)
10:30-10:50 Multidisciplinary approach in HCC treatment: various combination strategies and new emerging MTAs in HCC treatment Masao Omata
(Kofu)
10:50-11:10 Application of new local ablation therapies in HCC: microwave RFA, cryotherapy, etc Hyunchul Rhim
(Seoul)
11:10-11:30 Comparision of transarterial approaches in HCC treatment: conventional TACE, DEB-TACE vs TARE Jin Wook Chung
(Seoul)
11:30-11:50 Immunotherapeutic approaches beyond molecular targeted agents in HCC Thomas Yau
(Hong Kong)
11:50-12:00 Q&As
Symposium LV-06
Nov. 17 (Sat)
14:00-15:30
Recent changes in the diagnosis and management of liver cirrhosis complication 101 (1F)
Chairperson(s) Barjesh Chander Sharma (New Delhi), Soon Koo Baik (Wonju)
14:00-14:20 Evolving definition and treatment paradigms of acute-on-chronic liver failure Shiv Kumar Sarin
(New Delhi)
14:20-14:40 Minimal/overt hepatic encephalopathy: diagnostic tools, who should be treated, and how Woong Ray Kim
(Redwood)
14:40-15:00 Management of refractory ascites Ashish Kumar
(New Delhi)
15:00-15:20 Recent advances in the management of variceal bleeding Yeon Seok Seo
(Seoul)
15:20-15:30 Q&As
Symposium LV-07
Nov. 18 (Sun)
13:30-15:00
Recent advances in liver diseases 101 (1F)
Chairperson(s) Osamu Yokosuka (Chiba), Moonseok Choi (Seoul)
13:30-13:50 Alcoholic liver disease and fecal transplant Shiv Kumar Sarin
(New Delhi)
13:50-14:10 Cholestatic liver disease Jidong Jia
(Beijing)
14:10-14:30 Update in drug induced liver injury Harshad Devarbhavi
(Bangalore)
14:30-14:50 Recent advances in interventional radiology for liver diseases Dong Il Gwon
(Seoul)
14:50-15:00 Q&As